Abstract
Dissolution testing has been recognized as an important tool in drug development and assessment of quality of pharmaceutical products both in case of novel drug product and interchangeability drug products. In vitro dissolution testing is one of the primary United States Pharmacopoeia/National Formulary (USP/ NF) test, which is performed to ensure that a drug product meet the USP/NF standards of identity, strength, quality, purity, stability and bioequivalence in case of interchangeable drug products. In vitro dissolution profile comparison of drug release can be used as a surrogate in formulation development and in vivo bioequivalence testing. The comparison of dissolution profiles is considered to be critical test for assessing the performance of a drug product. In the present study, in vitro dissolution profile of two in-house batches, containing Biopharmaceutical Classification System (BCS) class 1 API (Zidovudine) was compared with reference product (Retrovir) by model independent approach to meet the requirements for biowaiver. Batch 2 of in-house formulation is considered to be similar to reference product and could be interchangeable.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
